Literature DB >> 28536827

Genetic Counselling for Maternally Inherited Mitochondrial Disorders.

Joanna Poulton1, Josef Finsterer2, Patrick Yu-Wai-Man3,4,5,6.   

Abstract

The aim of this review was to provide an evidence-based approach to frequently asked questions relating to the risk of transmitting a maternally inherited mitochondrial disorder (MID). We do not address disorders linked with disturbed mitochondrial DNA (mtDNA) maintenance, causing mtDNA depletion or multiple mtDNA deletions, as these are autosomally inherited. The review addresses questions regarding prognosis, recurrence risks and the strategies available to prevent disease transmission. The clinical and genetic complexity of maternally inherited MIDs represent a major challenge for patients, their relatives and health professionals. Since many of the genetic and pathophysiological aspects of MIDs remain unknown, counselling of affected patients and at-risk family members remains difficult. MtDNA mutations are maternally transmitted or, more rarely, they are sporadic, occurring de novo (~25%). Females carrying homoplasmic mtDNA mutations will transmit the mutant species to all of their offspring, who may or may not exhibit a similar phenotype depending on modifying, secondary factors. Females carrying heteroplasmic mtDNA mutations will transmit a variable amount of mutant mtDNA to their offspring, which can result in considerable phenotypic heterogeneity among siblings. The majority of mtDNA rearrangements, such as single large-scale deletions, are sporadic, but there is a small risk of recurrence (~4%) among the offspring of affected women. The range and suitability of reproductive choices for prospective mothers is a complex area of mitochondrial medicine that needs to be managed by experienced healthcare professionals as part of a multidisciplinary team. Genetic counselling is facilitated by the identification of the underlying causative genetic defect. To provide more precise genetic counselling, further research is needed to clarify the secondary factors that account for the variable penetrance and the often marked differential expressivity of pathogenic mtDNA mutations both within and between families.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28536827     DOI: 10.1007/s40291-017-0279-7

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  88 in total

1.  The mitochondrial DNA genetic bottleneck results from replication of a subpopulation of genomes.

Authors:  Timothy Wai; Daniella Teoli; Eric A Shoubridge
Journal:  Nat Genet       Date:  2008-12       Impact factor: 38.330

2.  Skewed segregation of the mtDNA nt 8993 (T-->G) mutation in human oocytes.

Authors:  R B Blok; D A Gook; D R Thorburn; H H Dahl
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

3.  Population prevalence of the MELAS A3243G mutation.

Authors:  Neil Manwaring; Michael M Jones; Jie Jin Wang; Elena Rochtchina; Chris Howard; Paul Mitchell; Carolyn M Sue
Journal:  Mitochondrion       Date:  2007-01-08       Impact factor: 4.160

Review 4.  Mitochondrial depletion syndromes in children and adults.

Authors:  Josef Finsterer; Uwe Ahting
Journal:  Can J Neurol Sci       Date:  2013-09       Impact factor: 2.104

5.  RNASEH1 Mutations Impair mtDNA Replication and Cause Adult-Onset Mitochondrial Encephalomyopathy.

Authors:  Aurelio Reyes; Laura Melchionda; Alessia Nasca; Franco Carrara; Eleonora Lamantea; Alice Zanolini; Costanza Lamperti; Mingyan Fang; Jianguo Zhang; Dario Ronchi; Sara Bonato; Gigliola Fagiolari; Maurizio Moggio; Daniele Ghezzi; Massimo Zeviani
Journal:  Am J Hum Genet       Date:  2015-06-18       Impact factor: 11.025

6.  Universal heteroplasmy of human mitochondrial DNA.

Authors:  Brendan A I Payne; Ian J Wilson; Patrick Yu-Wai-Man; Jonathan Coxhead; David Deehan; Rita Horvath; Robert W Taylor; David C Samuels; Mauro Santibanez-Koref; Patrick F Chinnery
Journal:  Hum Mol Genet       Date:  2012-10-16       Impact factor: 6.150

7.  Towards germline gene therapy of inherited mitochondrial diseases.

Authors:  Masahito Tachibana; Paula Amato; Michelle Sparman; Joy Woodward; Dario Melguizo Sanchis; Hong Ma; Nuria Marti Gutierrez; Rebecca Tippner-Hedges; Eunju Kang; Hyo-Sang Lee; Cathy Ramsey; Keith Masterson; David Battaglia; David Lee; Diana Wu; Jeffrey Jensen; Phillip Patton; Sumita Gokhale; Richard Stouffer; Shoukhrat Mitalipov
Journal:  Nature       Date:  2012-10-24       Impact factor: 49.962

8.  MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins.

Authors:  Sarah E Calvo; Karl R Clauser; Vamsi K Mootha
Journal:  Nucleic Acids Res       Date:  2015-10-07       Impact factor: 16.971

9.  Modulating mitochondrial quality in disease transmission: towards enabling mitochondrial DNA disease carriers to have healthy children.

Authors:  Alan Diot; Eszter Dombi; Tiffany Lodge; Chunyan Liao; Karl Morten; Janet Carver; Dagan Wells; Tim Child; Iain G Johnston; Suzannah Williams; Joanna Poulton
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

10.  A national perspective on prenatal testing for mitochondrial disease.

Authors:  Victoria Nesbitt; Charlotte L Alston; Emma L Blakely; Carl Fratter; Catherine L Feeney; Joanna Poulton; Garry K Brown; Doug M Turnbull; Robert W Taylor; Robert McFarland
Journal:  Eur J Hum Genet       Date:  2014-03-19       Impact factor: 4.246

View more
  21 in total

Review 1.  Cerebral imaging in paediatric mitochondrial disorders.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Neuroradiol J       Date:  2018-07-06

2.  Assisted reproductive technologies to prevent human mitochondrial disease transmission.

Authors:  Andy Greenfield; Peter Braude; Frances Flinter; Robin Lovell-Badge; Caroline Ogilvie; Anthony C F Perry
Journal:  Nat Biotechnol       Date:  2017-11-09       Impact factor: 54.908

3.  Polymegathism as a biomarker of mitochondrial disorders.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-13       Impact factor: 3.117

4.  Viability of diffusion tensor imaging for assessing retro-chiasmatic involvement in Kearns-Sayre syndrome remains elusive.

Authors:  Josef Finsterer
Journal:  Neuroradiology       Date:  2019-12-06       Impact factor: 2.804

5.  The Apparent Beneficial Effect of L-arginine for Stroke-like Lesions can Be Accidental.

Authors:  Josef Finsterer; Sinda Zarrouk
Journal:  Neurohospitalist       Date:  2022-04-22

6.  Cluster headache as a manifestation of a stroke-like episode in a carrier of the MT-ND3 variant m.10158T>C.

Authors:  Josef Finsterer
Journal:  World J Clin Cases       Date:  2020-01-06       Impact factor: 1.337

7.  Clinical utility gene card for: inherited optic neuropathies including next-generation sequencing-based approaches.

Authors:  Neringa Jurkute; Anna Majander; Richard Bowman; Marcela Votruba; Stephen Abbs; James Acheson; Guy Lenaers; Patrizia Amati-Bonneau; Mariya Moosajee; Gavin Arno; Patrick Yu-Wai-Man
Journal:  Eur J Hum Genet       Date:  2018-08-24       Impact factor: 4.246

8.  Unmasking fibromyalgia as a mitochondrial disorder requires search for more than a single variant or single mtDNA deletions.

Authors:  Josef Finsterer
Journal:  Indian J Med Res       Date:  2020-10       Impact factor: 2.375

9.  Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Mol Genet Metab Rep       Date:  2017-08-07

Review 10.  Involvement of the Spinal Cord in Mitochondrial Disorders.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  J Neurosci Rural Pract       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.